HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial.

AbstractBACKGROUND:
The standard therapy for human immunodeficiency virus (HIV)-associated cryptococcal meningitis of amphotericin B (AmB; 0.7 mg/kg per day) plus flucytosine frequently takes >2 weeks to sterilize the cerebral spinal fluid, and acute mortality remains high. A dosage range for AmB of 0.7-1 mg/kg per day is noted in current guidelines, but there are no data comparing 0.7 mg/kg per day with 1 mg/kg per day.
METHODS:
Sixty-four HIV-seropositive, antiretroviral therapy-naive patients in Cape Town, South Africa, who experienced their first episode of cryptococcal meningitis during the period May 2005-June 2006 were randomized to receive either (1) AmB, 0.7 mg/kg per day, plus flucytosine, 25 mg/kg 4 times per day (group 1; 30 patients); or (2) AmB, 1 mg/kg per day, plus flucytosine, 25 mg/kg 4 times per day (group 2; 34 patients). Regimens were given for 2 weeks, followed by treatment with oral fluconazole. The primary outcome measure was early fungicidal activity, as determined by results of serial, quantitative cerebral spinal fluid cryptococcal cultures. Secondary outcome measures were safety and mortality. The median duration of follow-up was 1 year.
RESULTS:
Early fungicidal activity was significantly greater for group 2 than for group 1 (mean +/- SD, -0.56 +/- 0.24 vs. -0.45 +/- 0.16 log cfu/mL of cerebral spinal fluid per day; P = .02). The incidence of renal impairment did not significantly differ between the 2 groups. Anemia was associated with female sex and, less strongly, with membership in group 2. Renal impairment and anemia reversed after the regimen was switched to fluconazole. Two- and 10-week mortality rates were 6% and 24%, respectively, with no difference between groups.
CONCLUSIONS:
AmB, 1 mg/kg per day, plus flucytosine is more rapidly fungicidal than is standard-dose AmB plus flucytosine. Because of its size, this study provides limited data on any difference in toxicity between the regimens, but toxicities were manageable and reversible.
CLINICAL TRIALS REGISTRATION NUMBER:
ISRCTN68133435 (http://www.controlled-trials.com).
AuthorsTihana Bicanic, Robin Wood, Graeme Meintjes, Kevin Rebe, Annemarie Brouwer, Angela Loyse, Linda-Gail Bekker, Shabbar Jaffar, Thomas Harrison
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 47 Issue 1 Pg. 123-30 (Jul 01 2008) ISSN: 1537-6591 [Electronic] United States
PMID18505387 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antifungal Agents
  • Hemoglobins
  • Amphotericin B
  • Creatinine
  • Flucytosine
Topics
  • AIDS-Related Opportunistic Infections (drug therapy)
  • Adult
  • Amphotericin B (administration & dosage, adverse effects, therapeutic use)
  • Anemia (chemically induced)
  • Antifungal Agents (administration & dosage, adverse effects, therapeutic use)
  • Cerebrospinal Fluid (microbiology)
  • Creatinine (blood)
  • Cryptococcus neoformans (drug effects, isolation & purification)
  • Female
  • Flucytosine (administration & dosage, therapeutic use)
  • Follow-Up Studies
  • Hemoglobins (analysis)
  • Humans
  • Male
  • Meningitis, Cryptococcal (drug therapy, mortality)
  • Renal Insufficiency (chemically induced)
  • Sex Factors
  • South Africa
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: